Papers/PMID:21908203
Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism.
Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation2012The record
3 findings · 1 compound · 3 endpoints
What it reported
How to read these marksWhat moved
3 findings
calciol — decreases C-reactive protein concentration
Evidence strength: very limited.Findingreplicated ×2“Additionally, we observed a significant reduction in high-sensitivity C-reactive protein levels after 3 months (median: 0.62 [0.05 to 29.6] mg/L vs. 0.32 [0.02 to 3.13] mg/L; P = .02) and after 6 months (median: 0.62 [0.05 to 29.6] mg/L vs. 0.50 [0.02 to 5.66] mg/L; P = .04) of cholecalciferol supplementation, as well as a significant reduction in interleukin-6 levels (median: 6.44 pg/mL vs. 3.83 pg/mL; P = .018) after 6 months of supplementation.”
Quoted verbatim from Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism.. - Study
- cohort
- Dose
- oral cholecalciferol once weekly, 50,000 IU for the first 12 weeks then 20,000 IU for the last 12 weeks
- Population
- Haemodialysis patients with hypovitaminosis D (25(OH)D <30 ng/mL) and iPTH <300 pg/mL, not receiving vitamin D therapy; single-group before-and-after comparison with baseline; hs-CRP reported at 3 and 6 months
Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism.2012PMID:2190820310.1053/j.jrn.2011.07.001Permalink
calciol — decreases interleukin-6 concentration
Evidence strength: very limited.Findingreplicated ×1“Additionally, we observed a significant reduction in high-sensitivity C-reactive protein levels after 3 months (median: 0.62 [0.05 to 29.6] mg/L vs. 0.32 [0.02 to 3.13] mg/L; P = .02) and after 6 months (median: 0.62 [0.05 to 29.6] mg/L vs. 0.50 [0.02 to 5.66] mg/L; P = .04) of cholecalciferol supplementation, as well as a significant reduction in interleukin-6 levels (median: 6.44 pg/mL vs. 3.83 pg/mL; P = .018) after 6 months of supplementation.”
Quoted verbatim from Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism.. - Study
- cohort
- Dose
- oral cholecalciferol once weekly, 50,000 IU for the first 12 weeks then 20,000 IU for the last 12 weeks
- Population
- Haemodialysis patients with hypovitaminosis D (25(OH)D <30 ng/mL) and iPTH <300 pg/mL, not receiving vitamin D therapy; single-group before-and-after comparison with baseline; IL-6 at 6 months
Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism.2012PMID:2190820310.1053/j.jrn.2011.07.001Permalink
calciol — increases serum 25-hydroxyvitamin D concentration
Evidence strength: very limited.Findingreplicated ×33“We observed a significant increase in serum 25(OH)D levels after 3 months (46.2 ± 14.4 ng/mL vs. 18.1 ± 6.6 ng/mL; P < .001) and after 6 months (40.4 ± 10.4 ng/mL vs. 18.1 ± 6.6 ng/mL; P < .001) of cholecalciferol supplementation.”
Quoted verbatim from Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism.. - Study
- cohort
- Dose
- oral cholecalciferol once weekly, 50,000 IU for the first 12 weeks then 20,000 IU for the last 12 weeks
- Population
- Haemodialysis patients with hypovitaminosis D (25(OH)D <30 ng/mL) and iPTH <300 pg/mL, not receiving vitamin D therapy; single-group before-and-after comparison with baseline
Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism.2012PMID:2190820310.1053/j.jrn.2011.07.001Permalink